HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM)

Clinical trials for HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM) explained in plain language.

Never miss a new study

Get alerted when new HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM) trials appear

Sign up with your email to follow new studies for HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Race to stop cancer before it starts: new drug trial aims to delay deadly myeloma

Prevention Not yet recruiting

This study is testing whether an experimental drug called linvoseltamab can delay the development of active multiple myeloma better than an existing drug, daratumumab. It involves 270 people diagnosed with high-risk smoldering multiple myeloma, a condition that often progresses t…

Matched conditions: HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM)

Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention

Last updated Apr 01, 2026 14:42 UTC

HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM)

Get alerted when new HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM) trials appear

Race to stop cancer before it starts: new drug trial aims to delay deadly myeloma